| 1 |
33536190 | Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. | 2021 Apr |
1 |
| 2 |
32540097 | Mutated lamin A modulates stiffness in muscle cells. | 2020 Aug 27 |
1 |
| 3 |
30969964 | Novel AU-rich proximal UTR sequences (APS) enhance CXCL8 synthesis upon the induction of rpS6 phosphorylation. | 2019 Apr |
1 |
| 4 |
31201369 | A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma. | 2019 Oct |
1 |
| 5 |
31461811 | [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer]. | 2019 Aug 25 |
2 |
| 6 |
31649535 | Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth. | 2019 |
1 |
| 7 |
28986121 | A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. | 2018 Jan |
1 |
| 8 |
29737325 | The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2018 May 8 |
2 |
| 9 |
29915160 | The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. | 2018 Aug 15 |
1 |
| 10 |
30414267 | Effects of Erythromycin on the Proliferation and Apoptosis of Cultured Nasal Polyp-Derived Cells and the Extracellular Signal-Regulated Kinase (ERK)/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. | 2018 Nov 10 |
1 |
| 11 |
25867065 | Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. | 2016 Jan 28 |
1 |
| 12 |
27670699 | Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. | 2016 Oct |
1 |
| 13 |
25624003 | Increasing progranulin levels and blockade of the ERK1/2 pathway: upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia. | 2015 Mar |
2 |
| 14 |
25857555 | TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation. | 2015 Jul |
1 |
| 15 |
25959272 | EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. | 2015 Dec |
1 |
| 16 |
24375836 | MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim. | 2014 Apr |
1 |
| 17 |
24939055 | Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. | 2014 Jun 17 |
1 |
| 18 |
25379021 | Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. | 2014 Oct |
1 |
| 19 |
23234544 | The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. | 2013 Mar 1 |
2 |
| 20 |
23255578 | Aggravation of inflammatory response by costimulation with titanium particles and mechanical perturbations in osteoblast- and macrophage-like cells. | 2013 Mar 1 |
1 |
| 21 |
23942066 | Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. | 2013 Sep 17 |
1 |
| 22 |
22068161 | Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene. | 2012 Feb 1 |
1 |
| 23 |
22260668 | Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. | 2012 Feb |
1 |
| 24 |
22821509 | The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. | 2012 Nov |
1 |
| 25 |
23362510 | Modeling of lamin A/C mutation premature cardiac aging using patient‐specific induced pluripotent stem cells. | 2012 Nov |
2 |
| 26 |
21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | 2011 Mar 29 |
1 |
| 27 |
21674991 | A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. | 2011 |
1 |
| 28 |
21899882 | Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. | 2011 Dec |
1 |
| 29 |
19804833 | Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. | 2010 Jan |
3 |
| 30 |
20806365 | Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. | 2010 Oct |
1 |
| 31 |
19366835 | In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. | 2009 May 1 |
1 |
| 32 |
19637312 | Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. | 2009 Nov 15 |
5 |
| 33 |
17510321 | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. | 2007 Sep 1 |
1 |
| 34 |
17699718 | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. | 2007 Aug |
3 |